Ligand begins Phase ll trial of LGD-6972 to treat type 2 diabetes mellitus
US-based biopharmaceutical company Ligand Pharmaceuticals Incorporated has begun a Phase ll clinical trial of its glucagon receptor antagonist LGD-6972 to treat type 2 diabetes mellitus (T2DM).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news
More News: Clinical Trials | Diabetes | Diabetes Mellitus | Diabetes Type 2 | Endocrinology | Pharmaceuticals